erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
"it's a very exciting time," klugman said. "this is exactly where we would like prenatal diagnosis to go -- to be able to act on it."
.
.
.